[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prime Gene Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,67,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100593950","phase-1-a-phase-i-clinical-trial-to-evaluate-the-single-dose-ascending-and-food-effects-of-pg-033-in-healthy-adults-100593950",false,"NCT07013097","A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults","A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PG-033 by Single Dose Administration and Food Effect in Healthy Volunteers","Inclusion Criteria:\n\n* 1\\. Read, understood, and signed an ICF before any investigational procedure(s) are performed.\n\n  2.Male or female aged 18 to 45 (including threshold). 3. For male subjects, the body weight should be ≥ 50.0 kg, and for female subjects, the body weight should be ≥ 45.0 kg. The body mass index (BMI) should be within the range of 19.0 to 26.0 kg\u002Fm²(including threshold).\n\n  4\\. Results of vital signs examination, physical examination, clinical laboratory tests (including blood routine examination, urine routine examination, blood biochemistry examination, coagulation function examination, thyroid function examination, etc.), chest X-ray, adrenal gland color ultrasound, etc. during the screening period show normal results or, if there are abnormalities, they are judged by the investigator to have no clinical significance.\n\n  5\\. Be willing to avoid pregnancy or voluntarily take effective contraceptive measures and have no sperm or egg donation plan from the signing of the informed consent form to three month after the last administration of the investigational medicinal product.\n\n  6\\. Be able to communicate well with the investigator and understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n* 1\\. Participants with abnormal electrocardiogram results during screening (e.g., QT\u002FQTcF \\> 440 ms, PR interval \\> 200 ms, QRS complex duration \\> 100 ms, clinically significant abnormalities of the P wave, clinically significant changes in the ST-T wave, etc.).\n\n  2\\. Participants known to be allergic to this product or related excipients; or participants with an allergic constitution (such as those who are allergic to two or more drugs or foods).\n\n  3\\. Participants with a history of chronic diseases or severe diseases in the circulatory, urinary, respiratory, hematological and lymphatic, endocrine, immune, mental and neurological, digestive systems, etc.\n\n  4\\. Participants who have undergone major surgery within 6 months before the first dose administration, or those who plan to have surgery during the study period, or those who have undergone surgery that, as judged by the investigator, will affect the evaluation of the drug's safety and pharmacokinetic characteristics.\n\n  5\\. Participants who have used any drugs (including any prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines) and health products within 2 weeks before the first dose administration.\n\n  6\\. Participants who have used any drugs that inhibit or induce the liver's metabolism of drugs (e.g., barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, selective serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.) within 4 weeks before the first dose administration.\n\n  7\\. Participants who are unable to stop consuming beverages and foods containing caffeine, alcohol, etc. (including chocolate, tea, coffee, cola, etc.), or foods that affect drug metabolism such as grapefruit, grapefruit products, pitaya, mango, pomelo, etc. from 48 hours before the first dose administration until the end of the trial, or those who are unable to stop consuming the above-mentioned diets from 48 hours before the first dose administration until the end of the trial.\n\n  8\\. Participants who have received live attenuated vaccine vaccination within 4 weeks before the first dose administration or those who need to receive live attenuated vaccine vaccination during the trial.\n\n  9\\. Participants with positive serological results for hepatitis B surface antigen (HBsAg), hepatitis C antibody, Treponema pallidum antibody, or human immunodeficiency virus antibody during screening.\n\n  10\\. Participants who have participated in other clinical trials within 3 months before the first dose administration.\n\n  11\\. Participants who have donated blood or lost a total of ≥ 400 mL of blood (excluding physiological blood loss in females) within 3 months before the first dose administration, received blood transfusion or used blood products, or those who plan to donate blood during the trial or within 1 month (30 days) after the end of the trial.\n\n  12\\. Participants who have consumed an average of more than 2 units of alcohol per day within 30 days before screening (1 unit ≈ 360 mL of beer or 45 mL of liquor with an alcohol content of 40% or 150 mL of wine), or those who cannot abstain from alcohol during the trial, or those with a positive result in the alcohol breath test.\n\n  13\\. Participants who have smoked an average of more than 5 cigarettes per day within 3 months before screening, or those who cannot stop smoking during the trial.\n\n  14\\. Participants with a history of drug abuse within 1 year before screening or those who tested positive for drug abuse screening.\n\n  15\\. Participants who cannot tolerate intravenous puncture\u002Findwelling needle or those with a history of fainting at the sight of needles or blood.\n\n  16\\. Participants with special dietary requirements and who cannot accept the unified diet.\n\n  17\\. Pregnant or lactating women; 18. Other participants determined by the investigator to be unsuitable for participation.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo. Meanwhile, the impact of a high-fat meal on the pharmacokinetics of PG-033 will also be evaluated. The research will also explore the potential metabolites and metabolic pathways of PG-033 within the human body，as well as investigate the effect of PG-033 on the QTc interval.",[28],"Lichen Simplex Chronicus",[30,28,31],"PG-033","Pruritus","RECRUITING","2026-05-31",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":36},"2025-05-23",{"date":40,"type":22},"2026-12-31",{"name":42,"class":43},"Prime Gene Therapeutics Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100640269","phase-1-a-study-to-evaluate-the-multiple-dose-ascending-of-pg-033-in-healthy-adult-participants-100640269","NCT07619183","A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.","A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PG-033 by Multiple Dose Administration in Healthy Adult Participants .","Inclusion Criteria:\n\n* 1\\. Read, understood, and signed an ICF before any investigational procedure(s) are performed..\n\n  2\\. Male or female aged 18 to 45 (including threshold). 3. For male participants, the body weight should be ≥ 50.0 kg, and for female paticipants, the body weight should be ≥ 45.0 kg. The body mass index (BMI) should be within the range of 19.0 to 26.0 kg\u002Fm²(including threshold) 4. Results of vital signs examination, physical examination, clinical laboratory tests (including blood routine examination, urine routine examination, blood biochemistry examination, coagulation function examination, thyroid function examination, etc.), chest X-ray, adrenal gland color ultrasound, etc. during the screening period show normal results or, if there are abnormalities, they are judged by the investigator to have no clinical significance..\n\n  5\\. Be willing to avoid pregnancy or voluntarily take effective contraceptive measures and have no sperm or egg donation plan from the signing of the informed consent form to three month after the last administration of the investigational medicinal product.\n\n  6\\. Be able to communicate well with the investigator and understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n* 1\\. Participants with clinically significant abnormal electrocardiogram results judged by the investigator during screening.\n\n  2\\. Participants known to be allergic to this product or related excipients; or participants with an allergic constitution (such as those who are allergic to two or more drugs or foods).\n\n  3\\. Participants with a history of chronic diseases or severe diseases in the circulatory, urinary, respiratory, hematological and lymphatic, endocrine, immune, mental and neurological, digestive systems, etc.\n\n  4\\. Participants who have undergone major surgery within 6 months before the first dose administration, or those who plan to have surgery during the study period, or those who have undergone surgery that, as judged by the investigator, will affect the evaluation of the drug's safety and pharmacokinetic characteristics.\n\n  5\\. Participants who have used any drugs (including any prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines) and health products within 2 weeks before the first dose administration.\n\n  6\\. Participants who have used any drugs that inhibit or induce the liver's metabolism of drugs (e.g., barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, selective serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.) within 4 weeks before the first dose administration.\n\n  7\\. Participants who are unable to stop consuming beverages and foods containing caffeine, alcohol, etc. (including chocolate, tea, coffee, cola, etc.), or foods that affect drug metabolism such as grapefruit, grapefruit products, pitaya, mango, pomelo, etc. from 48 hours before the first dose administration until the end of the trial, or those who are unable to stop consuming the above-mentioned diets from 48 hours before the first dose administration until the end of the trial.\n\n  8\\. Participants who have received live attenuated vaccine vaccination within 4 weeks before the first dose administration or those who need to receive live attenuated vaccine vaccination during the trial.\n\n  9\\. Participants with positive serological results for hepatitis B surface antigen (HBsAg), hepatitis C antibody, Treponema pallidum antibody, or human immunodeficiency virus antibody during screening.\n\n  10\\. Participants who have participated in other clinical trials within 3 months before the first dose administration.\n\n  11\\. Participants who have donated blood or lost a total of ≥ 400 mL of blood (excluding physiological blood loss in females) within 3 months before the first dose administration, received blood transfusion or used blood products, or those who plan to donate blood during the trial or within 1 month (30 days) after the end of the trial.\n\n  12\\. Participants who have consumed an average of more than 2 units of alcohol per day within 30 days before screening (1 unit ≈ 360 mL of beer or 45 mL of liquor with an alcohol content of 40% or 150 mL of wine), or those who cannot abstain from alcohol during the trial, or those with a positive result in the alcohol breath test.\n\n  13\\. Participants who have smoked an average of more than 5 cigarettes per day within 3 months before screening, or those who cannot stop smoking during the trial.\n\n  14\\. Participants with a history of drug abuse within 1 year before screening or those who tested positive for drug abuse screening.\n\n  15\\. Participants who cannot tolerate intravenous puncture\u002Findwelling needle or those with a history of fainting at the sight of needles or blood.\n\n  16\\. Participants with special dietary requirements and who cannot accept the unified diet.\n\n  17\\. Pregnant or lactating women; 18. Other participants determined by the investigator to be unsuitable for participation.",{"count":53,"type":22},30,[25],"The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.",[28],[30,28,31],"NOT_YET_RECRUITING","2026-05-27",{"date":61,"type":36},"2026-06-01",{"date":63,"type":22},"2026-06-04",{"date":65,"type":22},"2026-12-30",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100604177","phase-3-a-phase-iii-study-to-assess-the-efficacy-and-safety-of-pg-011-nasal-spray-in-adults-with-moderate-to-severe-seasonal-allergic-rhinitis-100604177","NCT07146126","A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb\u002FIII Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","Pumecitinib","Inclusion Criteria:\n\n1. Male or female aged 18 to 65 (including threshold).\n2. Reflective total nasal symptom score ( rTNSS) score≥ 6 and retrospective nasal obstruction ≥ 2 on the day of screening visit, D-4 and D1. Meanwhile, the baseline average rTNSS score(Calculated as the average of rTNSS score of D-3, D-2, D-1 morning, D-1 evening, and D1 morning) ≥ 6\n3. History of SAR for at least 2 years. and positive results for any local allergen in the current season tested by either the skin prick test (SPT) (where the wheal diameter is at least 5 mm larger than that of the negative control) or the serum - specific IgE (sIgE) test (the sIgE test results obtained within ≤ 1 year before random enrollment are acceptable).\n4. Willingness to avoid pregnancy or fathering children from the signing of the informed consent form until three month after after the end of the study.\n5. Willing to sign the informed consent form and abide by the research protocol.\n\nExclusion Criteria:\n\n1. Participants are diagnosed of active or latent tuberculosis infection.\n2. Participants are diagnosed of moderate to severe asthma.\n3. Participants who had active pulmonary diseases or infections, upper respiratory tract infections or sinus infections within 2 weeks before screening, and\u002For those who had respiratory infections during the lead-in period.\n4. Participants received nasal or sinus surgery within 3 months before screening or had nasal trauma that had not fully healed.\n5. Any nasal mucosal erosion, nasal septal ulcer or nasal septal perforation, as judged by the investigator, may affect the deposition of drugs in the intranasal, such as acute or chronic sinusitis, drug-induced rhinitis, nasal polyps, etc.\n6. Participants has ocular herpes simplex or other ocular infections (except seasonal allergic conjunctivitis).\n7. Participants with facial or systemic fungal, bacterial, viral or parasitic infections, or oral infections that had not been cured and still required continuous treatment within 4 weeks before screening.\n8. Participants have severe diseases such as central nervous system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system or blood system, which may affect the judgment of efficacy and safety .\n9. Participants who were infected with human immunodeficiency virus (HIV) at the time of screening, those in the active stage of hepatitis C virus (HCV) infection, those in the active stage of hepatitis B virus (HBV) infection (HBV - DNA \\> 2000 IU\u002FmL or 10⁴ copies\u002FmL), or those with positive Treponema pallidum antibody indicating an active stage of infection.\n10. Any drug treatments before lead-in period, such as use of nasal or systemic decongestants and anticholinergic drugs within 3 days, use of antihistamines such as cetirizine, fexofenadine, and loratadine within 5 days, systemic use of glucocorticoids within 4 weeks, mast cell stabilizers, tricyclic antidepressants, and leukotriene receptor antagonists within 2 weeks, and use of anti - allergic Chinese herbal medicines within 2 weeks, use of anti-interleukin-4 receptor α subunit (IL-4Rα) monoclonal antibody such as thymic matrix lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody, other monoclonal antibody, or other biologics within 10 weeks or 5 half-lives (whichever is longer).\n11. During the trial, participants who cannot stop using JAK inhibitors, tricyclic antidepressants, glucocorticoids, decongestants, antihistamines (except loratadine, which is a rescue drug required during the treatment), leukotriene receptor antagonists, mast cell stabilizers (including sodium cromoglycate, nedocromil sodium, tetrazolium chromone, nedocromil sodium, pemirolast potassium, and tranilast, etc.), anticholinergic drugs, anti - allergic Chinese herbal medicines, and those who cannot stop using nasal irrigation.\n12. Participants who have undergone desensitization therapy or received immunotherapy within 6 months prior to screening.\n13. Participants who are known or judged by the investigator to potentially have an allergic reaction to the active ingredients or excipients of the investigational drug.\n14. Participants who have a history of intolerance to intranasal administration.\n15. Participants who plan to travel outside the local area for 2 consecutive days or more during the trial.\n16. Participants who have participated in other clinical studies of investigational drugs or medical devices within 3 months prior to screening and have used investigational products.\n17. Participants who have a history of drug abuse or alcoholism within 1 year prior to screening\n18. Female participants who are breastfeeding or pregnant at the time of screening\n19. Reproductive - age participants (male or female) who plan to become pregnant, breastfeed, or donate sperm\u002Feggs during the study or within 1 month after the study ends\n20. Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for participation in the study","65 Years",{"count":77,"type":22},600,[79],"PHASE3","The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb\u002FIII study encompassing a phase IIb and a phase III component, phase IIb is a dose-ranging part and has been done, and phase III is a pivotal study part which is registered this time.\n\nThe goal of this phase III study is to evaluate the efficacy, safety, and pharmacokinetics of PG-011 nasal spray for treating adults with moderate to severe seasonal allergic rhinitis (SAR). Investigators will compare PG-011 nasal spray to a placebo (a look-alike substance that contains no drug) to see if PG-011 nasal spray works to treat moderate to severe seasonal allergic rhinitis",[82,83],"Seasonal Allergic Rhinitis","SAR",[83,85,82,73],"PG-011","2025-08-21",{"date":88,"type":36},"2025-08-28",{"date":90,"type":22},"2025-09-15",{"date":92,"type":22},"2026-07-30",{"name":42,"class":43},38,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100561247","phase-3-a-study-to-assess-the-efficacy-and-safety-of-pg-011-gel-in-adolescents-and-adults-with-atopic-dermatitis-100561247","NCT06587685","A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of PG-011 Gel With 8 Weeks Treatment and Extension Safety Study to 52 Weeks in Adolescents and Adults With Atopic Dermatitis","Inclusion Criteria:\n\n1. 12 years old≤ age ≤ 75 years old (including threshold), male or female.\n2. Participants diagnosed of atopic dermatitis (AD) as defined by the Williams diagnostic criteria.\n3. AD\u002Feczema duration of at least 1 year for adults and 6 months for adolescents.\n4. IGA score of 2 (mild) or 3 (moderate) at the screening day and day 1.\n5. %BSA (excluding the scalp) with AD involvement of at least 10% and up to 20%.\n6. Willingness to avoid pregnancy or fathering children based on the criteria as outlined in the protocol.\n\nExclusion Criteria:\n\n1. Participant has unstable course of AD (spontaneously improving or rapidly deteriorating).\n2. Immunocompromised (e.g. lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).\n3. Any other concomitant skin disorder(e.g. generalized erythroderma, Netherton syndrome, acne, psoriasis, urticaria, pigmentation or extensive scarring）, in the opinion of investigator, may interfere with the evaluation of AD lesions or compromise participant safety.\n4. Participant with chronic or acute infection needs to be treated with systemic antibiotics, antiviral drugs, antiparasitic drugs, anti-antigenic animal drugs or antifungal drugs within 2 weeks before randomization.\n5. Participant with active acute\u002Fchronic bacterial, fungal or viral skin infections (such as herpes simplex, herpes zoster, chickenpox, etc.) before randomization, including but not limited to clinically significant secondary infections of AD or other infections associated with AD lesions.\n6. Participant has human immunodeficiency virus (HIV) infection, active hepatitis C virus (HCV) infection (anti-HCV positive), active hepatitis B virus (HBV) infection (HBV-DNA \\> 2000IU\u002Fml) or Treponema pallidum antibody positive and showing active.\n7. Clinically significant or uncontrolled cardiovascular disease (including but not limited to unstable angina, acute myocardial infarction, heart failure, arrhythmia requiring treatment or uncontrolled hypertension).\n8. Participant has serious diseases or complications of the central nervous system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system or immune system, blood system, etc., and in the opinion of the investigator, may affect the judgment of efficacy and safety .\n9. Participant has mental illness such as anxiety disorder, depression, or other conditions that affect the compliance and may interfere with the implementation of clinical research.\n10. Participant has a history of malignant tumors before randomization.\n11. Participant has severe and uncontrolled disease that may affect safety, trial compliance, affect the evaluation of endpoints, and require the use of drugs that are not allowed in the protocol.\n12. Female participant who is lactating or pregnant at the time of screening.\n13. Any situation affects the safety and efficacy evaluation of the study drug judged by investigator.\n14. Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for participation in the study.","12 Years","75 Years",{"count":105,"type":22},472,[79],"This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb\u002FIII study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic Dermatitis. It consists of phase IIb and phase III parts, phase IIb is a dose-ranging part and has been done, and phase III is a pivotal study part which is registered this time.\n\nThe goal of this phase III clinical trial is to learn if PG-011gel works to treat mild to moderate Atopic Dermatitis in adolescents and adults by topical use. It will also learn about the safety of PG-011gel. Investigators will compare PG-011gel to a placebo (a look-alike substance that contains no drug) to see if PG-011gel works to treat mild to moderate Atopic Dermatitis.\n\nParticipants will:\n\n* Use PG-011gel or a placebo twice daily for initial 8 weeks, and followed by using PG-011 gel for all of the participants till 52-week.\n* Visit the clinic at weeks 1, 2, 4 and 8 for checkups and tests, and followed by visiting the clinic every 4 weeks till 52-week.\n* Keep a diary of their symptoms.",[109],"Atopic Dermatitis",[109,85,73,111,112],"Atopic","Dermatitis","2025-05-19",{"date":115,"type":36},"2025-05-20",{"date":117,"type":36},"2024-03-15",{"date":119,"type":22},"2026-01-15",{"name":42,"class":43},""]